155 related articles for article (PubMed ID: 18193718)
1. Molecularly targeted therapy in myeloid leukaemias.
Craddock C
Clin Med (Lond); 2007 Dec; 7(6):632-5. PubMed ID: 18193718
[No Abstract] [Full Text] [Related]
2. Targeting cancers with tyrosine kinase inhibitors: lessons learned from chronic myeloid leukaemia.
Mughal TI; Goldman JM
Clin Med (Lond); 2006; 6(6):526-8. PubMed ID: 17228548
[No Abstract] [Full Text] [Related]
3. Anti-cancer drug success emerges from molecular biology origins.
Pestell K
Trends Pharmacol Sci; 2001 Jul; 22(7):342. PubMed ID: 11431023
[No Abstract] [Full Text] [Related]
4. New drugs in acute myeloid leukemia.
Grever MR
Clin Adv Hematol Oncol; 2003 Aug; 1(8):456-9. PubMed ID: 16258431
[No Abstract] [Full Text] [Related]
5. [Clinical use of tyrosine kinase inhibitors for treatment of myeloid leukemias].
Tojo A
Nihon Rinsho; 2009 Oct; 67(10):1926-31. PubMed ID: 19860192
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
Malagola M; Martinelli G; Rondoni M; Paolini S; Gaitani S; Arpinati M; Piccaluga PP; Amabile M; Basi C; Ottaviani E; Candoni A; Gottardi E; Cilloni D; Bocchia M; Saglio G; Lauria F; Fanin R; Visani G; Marrè MC; Maderna M; Rancati F; Vinaccia V; Russo D; Baccarani M
Blood; 2005 Jan; 105(2):904; author reply 905. PubMed ID: 15632213
[No Abstract] [Full Text] [Related]
7. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Druker BJ
Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
[TBL] [Abstract][Full Text] [Related]
8. Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia.
Ueda K; Horiike S; Zen K; Misawa S; Taniwaki M
Leuk Lymphoma; 2006 Sep; 47(9):1967-9. PubMed ID: 17065015
[No Abstract] [Full Text] [Related]
9. Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer?
DeAngelo DJ; Ritz J
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):1-3. PubMed ID: 14734443
[No Abstract] [Full Text] [Related]
10. Chronic myeloid leukemia. Sceptical scientists.
Druker BJ
Lancet; 2001 Dec; 358 Suppl():S11. PubMed ID: 11784560
[No Abstract] [Full Text] [Related]
11. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib.
Heartin E; Walkinshaw S; Clark RE
Leuk Lymphoma; 2004 Jun; 45(6):1307-8. PubMed ID: 15360020
[No Abstract] [Full Text] [Related]
12. [Treatment for de novo chronic myeloid leukemia in chronic phase].
Hirase C; Matsumura I
Nihon Rinsho; 2012 Apr; 70 Suppl 2():298-303. PubMed ID: 23133971
[No Abstract] [Full Text] [Related]
13. [Chronic myeloid leukemia and targeted therapies: too many choices?].
Etienne G; Huguet F
Med Sci (Paris); 2010 Nov; 26(11):911-4. PubMed ID: 21106170
[No Abstract] [Full Text] [Related]
14. David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies.
Druker BJ
J Clin Oncol; 2003 Dec; 21(23 Suppl):239s-245s. PubMed ID: 14645403
[No Abstract] [Full Text] [Related]
15. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
White DL
Leuk Lymphoma; 2008 Jun; 49(6):1022-3. PubMed ID: 18452091
[No Abstract] [Full Text] [Related]
16. 3. Imatinib therapy in chronic myelogenous leukemia.
Jinnai I
Intern Med; 2007; 46(2):95-7. PubMed ID: 17220607
[No Abstract] [Full Text] [Related]
17. Imatinib: resisting the resistance.
Rothberg PG
Leuk Res; 2003 Nov; 27(11):977-8. PubMed ID: 12859989
[No Abstract] [Full Text] [Related]
18. Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months.
Cannella L; Breccia M; Loglisci G; Federico V; Santopietro M; Alimena G
Acta Oncol; 2010 Apr; 49(3):399-400. PubMed ID: 20105089
[No Abstract] [Full Text] [Related]
19. [Tyrosine kinase inhibitors].
Yagasaki F
Nihon Naika Gakkai Zasshi; 2007 Jul; 96(7):1411-9. PubMed ID: 17682429
[No Abstract] [Full Text] [Related]
20. Nilotinib as first-line therapy for chronic myeloid leukemia.
Vaid A
Indian J Cancer; 2011; 48(4):438-45. PubMed ID: 22293257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
